Personalis ( PSNL ) is a liquid biopsy company that is initially targeting the MRD and drug research markets. While competition in these markets is fierce, Personalis is differentiated by its whole genome sequencing approach, which should benefit fromRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying ...